As a new foreign trade service provider driven by both technology commercialization and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply original factory goods of acetyl L-carnitine hydrochloride from multiple well-known brands. As a tech-driven foreign trade service provider, HiSiaddi has repeatedly proposed formulation optimization schemes and application improvement suggestions for acetyl L-carnitine hydrochloride products through technological cooperation with manufacturers and precise insight into market demands. Below is a consultation case of formulation optimization for acetyl L-carnitine hydrochloride products handled by HiSiaddi.
Please contact HiSiaddi customer service if you need more formulation optimization consultation services.
The cooperating client is NUTRAFARM pharmaceutical enterprise based in Madrid, Spain. With 26 years of deep engagement in R&D and production of prescription-grade brain health dietary supplements, medical sustained-release tablets and oral nutrient solutions across the Iberian Peninsula, its products are stocked in public hospital pharmacies in Spain and high-end health product supermarket chains across the EU. Raw materials comply with EP, USP Pharmacopoeia, EFSA raw material control, TSE/BSE animal-free standards and EU clean label regulations. Its two flagship finished products are 500mg enteric sustained-release tablets and high-concentration oral nutrient solutions, with a stable annual purchase volume of 32 tons of acetyl L-carnitine hydrochloride, exclusively adopting pharmaceutical-grade refined enzymatic raw materials, distinct from low-end purchasers of generic health products.
The client had long sourced raw materials from German pharmaceutical manufacturers before switching to Chinese-origin raw materials to cut supply chain costs and shorten delivery cycles. After purchasing conventional pharmaceutical-grade acetyl L-carnitine hydrochloride from two domestic manufacturers, three major production failures broke out successively during mass production: tablet sticking during tableting, unstable tablet weight fluctuation and flocculent precipitation & delamination of oral liquid under low-temperature storage. The client’s production lines were shut down for debugging, resulting in losses exceeding 68,000 EUR from auxiliary material waste and semi-finished product scrapping, and mass production of its mature self-developed formulations had to be suspended. Repeated adjustments to auxiliary material ratios by the client’s R&D team failed to eliminate the root causes. Domestic raw material manufacturers could only guarantee compliance of content indicators, lacking technical capabilities for downstream formulation application and unable to optimize physical properties from the raw material end. The client fully entrusted HiSiaddi Foreign Trade to conduct full-process technical services covering raw material traceability, fault troubleshooting, collaborative formulation optimization and raw material process improvement.
The client’s mature formulations achieved stable mass production before switching to Chinese raw materials, while concentrated formulation failures emerged after replacement, all caused by mismatches between raw material powder indicators, trace impurities, dissolution characteristics and the formulation system:
1. Sticking during automated sustained-release tableting and excessive tablet weight deviation: Raw material powder has an angle of repose of 37.8° with widely varying particle sizes and poor flowability, leading to uneven blanking of high-speed automated tablet presses and RSD of tablet weight >5%, exceeding the EU Pharmacopoeia control standard of ≤3%. Raw materials rapidly absorb moisture and agglomerate in high-humidity production workshops, causing frequent powder adhesion to molds requiring mold cleaning every 3 hours and halving production capacity. Tablet hardness fluctuates sharply with unstable disintegration time limits. Conventional domestic raw materials only control content without customized powder modification for sustained-release formulations.
2. Flocculent precipitation of acidic oral liquid under low-temperature storage: The client’s 25% high-concentration acidic nutrient solution formulation remains clear and transparent at room temperature, yet white flocculent precipitates form after 7~10 days of storage at 5°C. Third-party testing confirmed precipitates derive from trace polar impurities and residual by-products of raw materials. The original total impurity level of 0.28% exceeds the client’s formulation tolerance threshold of 0.15%, and trace unsaturated carnitine derivatives slowly precipitate in weak acid systems.
3. Discoloration during compound formulation compounding (yellowing after storage with B vitamins): Residual trace free hydrochloric acid and inorganic chloride ions in acetyl L-carnitine hydrochloride cause yellowing of finished products after 30 days of light-proof storage when compounded with Vitamin B6 and nicotinamide, failing to meet the appearance standards of finished products specified by Spanish Pharmacopoeia. Multiple fine-tunings of buffer salt and antioxidant auxiliary material addition by the client failed to improve the issue.
HiSiaddi set up a special team consisting of API process engineers, formulation formulation consultants and EU compliance specialists to troubleshoot root causes in three steps, simultaneously guiding upstream manufacturers to optimize raw material processes and coordinating with the client to fine-tune auxiliary material systems of terminal formulations to resolve technical pain points bidirectionally:
1. Two batches of raw materials were submitted for full testing covering HPLC impurities, powder properties, residual solvents and chloride ions: total impurities reached 0.27% with single unknown impurity of 0.07% (exceeding standard); angle of repose 37.5° with excessive fine powder proportion and low critical moisture absorption humidity, leading to easy water absorption in workshop environments; excessive free chloride ions identified as core triggers of liquid precipitation and compound discoloration.
2. Root cause clarification: General crystallization processes of domestic manufacturers only guarantee compliance of content indicators without deep impurity removal and powder shaping. Their physical properties match general food formulations but fail to adapt to the client’s high-purity pharmaceutical sustained-release and high-concentration acidic liquid formulations.
HiSiaddi coordinated designated enzymatic manufacturers to fine-tune process parameters in refining, crystallization and drying sections without modifying main mass production lines:
1. Three-stage chromatographic deep impurity removal: Add an additional polar resin adsorption process on the basis of original two-stage resin purification to remove trace by-products and inorganic chloride salts, strictly controlling total impurities ≤0.13% and single impurity <0.04%, eliminating root triggers of liquid precipitation and compound discoloration;
2. Gradient temperature-controlled crystallization for powder modification: Optimize cooling rate and stirring speed to control grain uniformity, followed by low-temperature air flow sieving to lock finished product angle of repose at 28~29° with full passing through 100-mesh sieve, achieving powder flowability compliant with automated tableting standards; optimize vacuum drying parameters to limit raw material moisture absorption weight gain <1% after 72 hours under 65% RH environment, adapting to the client’s high-humidity production workshop and eliminating sticking caused by moisture absorption;
3. Upgrading desalination process: Optimize alcohol washing processes to control residual free hydrochloric acid and chloride ions, resolving oxidative yellowing issues during compounding with B vitamins. After 3 rounds of small sample delivery to the client for formulation pilot testing, all physicochemical indicators of raw materials reached customized specifications.
Without altering the main framework of the client’s original formulations, HiSiaddi provided lightweight formulation optimization suggestions combining new raw material characteristics:
1. Tablet formulation: Slightly increase the proportion of microcrystalline cellulose and pregelatinized starch, reduce magnesium stearate dosage by 0.2%. Combined with excellent flowability of optimized raw materials, RSD of tablet weight is stably controlled within 2.1%, completely eliminating sticking and unstable disintegration failures;
2. Oral liquid formulation: Fine-tune the pH of citric acid-sodium citrate buffer system by ±0.1. With low-impurity optimized raw materials, additional chelating agents can be canceled, and no delamination or precipitation occurs after 90 days of storage at 5°C;
3. Premixed compound formulation: Adjust vitamin feeding sequence — pre-mix acetylcarnitine with buffer salts before adding B vitamin components to isolate direct contact with trace acidic components, preventing yellowing of finished products during long-term storage.
After formulation finalization, the first batch of 5.2 tons of optimized-specification raw materials was delivered to the client’s factory in Spain. Smooth mass production was achieved on all three tablet and oral liquid production lines at one time, with all finished product indicators passing incoming inspections of Spanish drug administration. The new product whose mass production had been suspended was successfully launched in public hospitals across Spain. The annual 32-ton order was split into 8 batches scheduled monthly in staggered shifts. HiSiaddi arranged third-party full-item SGS testing for each batch before delivery, supporting EP-grade COA, full-process traceability documents and animal-free statements. Compared with German imported raw materials, the client’s overall procurement cost decreased by 24.7%, and ocean delivery cycle was shortened from 72 days to 35 days.
1. NUTRAFARM of Spain completely replaced German raw material sources, with 100% of its acetyl L-carnitine hydrochloride demand sourced from customized domestic raw materials coordinated by HiSiaddi. In the following year, it added customized demand for ultra-low impurity ultra-fine powder specially for infant drops, with an additional annual procurement order of 11 tons;
2. The client fully entrusted HiSiaddi with raw material selection and formulation technical coordination for functional raw materials such as L-carnitine tartrate and γ-aminobutyric acid. Relying on the technical implementation results of this project, HiSiaddi assisted manufacturers in perfecting standardized processes for high-end formulation-specific grades, successfully developing two equivalent high-end pharmaceutical clients in Portugal and France.
Most domestic manufacturers of acetyl L-carnitine hydrochloride focus on mass production of general food-grade products, only controlling content indicators and lacking R&D capabilities for downstream tablet and oral liquid formulation applications. Their raw material physical properties and trace impurity indicators cannot match high-end European pharmaceutical formulations. Equipped with mature terminal formulations, overseas high-end pharmaceutical enterprises lack familiarity with process shortcomings of domestic raw materials, leading to mass production failures after switching supply sources. Breaking the traditional foreign trade model of only raw material sales, HiSiaddi connects bidirectional technical service chains covering upstream raw material production process optimization and downstream terminal formulation fine-tuning. It not only helps overseas mid-to-high-end clients rapidly resolve mass production technical barriers and recover production losses, but also assists domestic API manufacturers to escape low-end homogeneous price competition and access high-value EU pharmaceutical raw material supply chains.
Please contact HiSiaddi customer service if you need more formulation optimization consultation services.
+86-13120989737 
info@hisiaddi.com 
English
